期刊文献+

垂体零细胞腺瘤内皮细胞特异性分子1的表达及其意义 被引量:2

Expression of endothelial cell specific molecnie-I and its clinical significance in pituitary null celladenomas
原文传递
导出
摘要 目的探讨垂体零细胞腺瘤(NCA)内皮细胞特异性分子I(ESM-1)表达及其与患者临床、病理特征的关系。方法对自2010年1月至2014年5月在南京军区福州总医院神经外科行经蝶窦入路显微手术切除的46例NCA标本,应用免疫组化染色检测ESM-1表达情况,并分析其与患者年龄(18-45岁16例、≥46岁30例1、性别(男29例,女17例)、肿瘤最大直径(1-3cm34例、≥3cm11例、〈1cm1例)、侵袭性(侵袭性NCA30例,非侵袭性NCA16例1及Ki.67指数(〈3%29例、≥3%17例1等临床、病理特征的关系。结果46例NCA标本中均可观察到血管内皮细胞ESM-1阳性表达,其中高表达(即中度阳性+强阳性)32例;40例NCA标本中肿瘤细胞ESM-1阳性表达,其中高表达25例;血管内皮细胞和肿瘤细胞间ESM-1高表达率比较差异无统计学意义(P〉O.05)。侵袭性NCA中血管内皮细胞ESM-1高表达率(23/30)显著高于非侵袭NCA(7/16),差异有统计学意义(P〈0.05);血管内皮细胞ESM-1高表达率在不同年龄、性别、肿瘤最大直径、Ki-67指数分组间比较差异均无统计学意义(P〉0.05)。肿瘤细胞ESM-1高表达率在不同年龄、性别、肿瘤最大直径、Ki-67指数及是否具有侵袭性分组间比较差异均无统计学意义(P〉0.05)。结论血管内皮细胞ESM.1表达可做为评估NCA侵袭性的分子生物学指标之一。 Objective To explore the expression of endothelial cell specific molecule-1 (ESM-1) and its clinical significance in pituitary null cell adenoma (NCA). Methods Forty-six cases of NCA specimens, collected from resection of pituitary tumor via microscopic transsphenoidal approach in our hospital from January 2010 to May 2014, were chosen in our study; ESM-1 expressions in the NCA specimens was detected by immunohistochemical S-P method, and the relations of expression results with gender (male: 29; female:17), age (18-45 years old: 16; ≥46 years old: 30), maximum tumor diameter (1-3 cm: 34; ≥ 3 cm: 11; 〈 1 cm: 1), invasion state (invasive NCA: 30; non-invasive NCA: 16), Ki-67 labeling index (〈3%: 29; ≥3%: 17) and pathological features were analyzed. Results ESM-1 expression was observed in endothelial cells and adenoma cells, with positive rates 100% and 86.96% (40/46); in the endothelial cells, high expression was noted in 32 patients; and in the adenoma cells, high expression was noted in 25 patients; no significant difference of high expression was noted between the two (P〉0.05). As compared with that ofnoninvasive NCA (7/16), the high expression of ESM-1 of invasive NCA (23/30) in endothelial cells was significantly increased (P〈0.05), while the high expression
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2016年第2期140-144,共5页 Chinese Journal of Neuromedicine
基金 南京军区“十二五”医学创新重点项目(20112034)福州总医院创新团队基金(2014-07)
关键词 垂体腺瘤 零细胞腺瘤 内皮细胞特异性分子1 侵袭性 Pituitary adenoma Null cell adenoma Endothelial cell specific molecule-l Invasiveness
  • 相关文献

参考文献16

  • 1Zhan X, Desiderio DM. The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas [J]. EPMA J, 2010, 1 (3): 439-459.
  • 2赵昭,金树梅,张学斌,唐帆,闫学江,薛凯,阎晓玲,姚鑫.2276例不同激素类型垂体腺瘤的临床及病理特点分析[J].中华神经医学杂志,2015,14(10):1031-1037. 被引量:9
  • 3Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype [J]. Cancer Res, 2009, 69 (3): 836-844.
  • 4Grigoriu BD, Depontieu, Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer [J]. Clin Cancer Res, 2006, 12(15): 4575-4582.
  • 5Rennel E, Mellberg S, Dimberg A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer[J]. Exp Cell Res, 2007, 313(7): 1285-1294.
  • 6Chen LY, Liu X, Wang SL, et al. Over-expression of the Endocan gene in endothelial cells fi:om hepatocellular carcinoma is associated with angiogenesis and tumour invasion [J]. J Int Med Res, 2010, 38(2): 498-510.
  • 7Cornelius A, Cortet-Rudelli C, Assaker R, et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma[J]. Brain Pathol, 2012, 22(6): 757-764.
  • 8Matano F, Yoshida D, Ishii Y, et al. Endocan, a new invasion and angiogenesis marker of pituitary adenomas[J].J Neurooncol, 2014, 117(3):485-491.
  • 9Shimoda Y, Ogawa Y, Watanabe M, et al. Clinicopathological investigation of vascular endothelial growth factor and von Hippel-Lindau gene-related protein expression in immunohistochemically negative pituitary adenorna-possible involvement in tumor aggressiveness[J]. Endocr Res, 2013, 38(4): 242-250.
  • 10Li Y, Zhou LP, Ma P, et al. Relationship of PTTG expression with tumor invasiveness and microvessel density of pituitary adenomas: a meta-analysis [J]. Genet Test Mol Biomarkers, 2014, 18 (4): 279-285.

二级参考文献29

  • 1Raappana A, Koivukangas J, Ebeling T, et al. Incidence of pituitary adenomas in Northern Finland in 1992-2007 [J]. J Clin Endocrinol Metab, 2010, 95(9): 4268-4275.
  • 2Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data[J]. Eur J Endocrinol, 2006, 154(5): 753-758.
  • 3Farrell WE, Simpson DJ, Bicknell JE, et al. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes[J]. Cancer Res, 1997, 57(13): 2703-2709.
  • 4Bates AS, Farrell WE, Bicknell EJ, et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker[J]. J Clin Endocrinol Metab, 1997, 82(3): 818-824.
  • 5Mou C, Han T, Zhao H, et al. Clinical features and immunohistochemical changes of pituitary apoplexy [J]. J Clin Neurosci, 2009, 16(1): 64-68.
  • 6Saeger W, Ludecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry[J]. Eur J Endocrinol, 2007, 156 (2): 203-216.
  • 7Jane JA, Laws ER. The surgical management of pituitary adenomas in a series of 3, 093 patients[J]. J Am Coil Surg, 2001, 193(6): 651-659.
  • 8Wade AN, Baccon J, Grady MS, et al. Clinically silent somatotroph adenomas arecommon[J]. Eur J Endocrinol, 2011,165(1): 39-44.
  • 9Ho DM, Hsu CY, Ting LT, et al . The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases [J]. Hum Pathol, 1997, 28(8): 905-911.
  • 10Cooper O, Geller JL, Melmed S. Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma [J]. Nat Clin Pract Endocrinol Metab, 2008, 4(4): 234-238.

共引文献8

同被引文献19

引证文献2

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部